Behavioural effects of selective serotonin reuptake inhibitors following direct micro injection into the left red nucleus of the rat

Journal of Psychopharmacology

Volumn 11, Issue 1, 1997, Pages 53-58

  Faherty, Ciaran J ^a   Earley, Bernadette ^a,b   Leonard, Brian E ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b GRANGE RESEARCH CENTRE   (Ireland)

Author keywords

ligand; Antidepressant; Behaviour; Dystonia; Red nucleus; Selective serotonin reuptake inhibitors (SSRIs)

Indexed keywords

CHLORPROMAZINE; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; GUANIDINE DERIVATIVE; HALOPERIDOL; PAROXETINE; PIPERIDINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; BODY POSTURE; CONTROLLED STUDY; DYSTONIA; FACE; GROOMING; INTRACEREBRAL DRUG ADMINISTRATION; MALE; MASTICATION; NONHUMAN; PRIORITY JOURNAL; RAT; SPASTICITY; TORTICOLLIS;

1-NAPHTHYLAMINE; ANIMALS; BEHAVIOR, ANIMAL; CHLORPROMAZINE; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; GUANIDINES; HALOPERIDOL; MALE; MICROINJECTIONS; MOTOR ACTIVITY; PAROXETINE; PIPERIDINES; POSTURE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SIGMA; RED NUCLEUS; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 0030975425     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988119701100114     Document Type: Article

References (58)

1. Arya D K, Szabadi E (1993) Dyskinesias associated with fluvoxamine. J Psychopharmac 13: 356-366
2. Baldessarini R J and Marsh E (1990) Fluoxetine and side effects. Archs Gen Psychiat 47: 191-192
3. Barg J, Belcheva M M, Bem W T, Lambourne B, Mclachlan J A, Tolman K C, Johnson F E, Coscia C J (1991) Desipramine modulation of sigma-peptide and opioid peptide receptor expression in glial cells. Peptides 12: 845-849
4. Beart P M, O'Shea R D Manallack D T (1989) Regulation of sigma receptors: high and low affinity agonist states, GTP shifts, and up-regulation by rimcazole and 1,3-di(2-tolyl) guanidine. J Neurochem 53: 779-788
5. Berardella A, Rothwell J C, Day B L, Marsden C D (1985) Pathophysiology of blepharospasm and oromandibular dystonia. Brain 108: 593-609
6. Blier P, Montigny C de, Chaput Y (1990) A role for the serotonin system in the mechanism of action of antidepressants. J Clin Psychiat 51: 14-20
7. Bouchard R H, Pourcher E, Vincent P (1989) Fluoxetine and extrapyramidal side effects. Am J Psychiat 146: 1352-1353
8. Budman C L, Brunn R D (1991) Persistent dyskiesia in a patient receiving fluoxetine. Am J Psychiat 148: 1403-1409
9. Byerley W F, McConnell E J, McCabe R T, DawsonT M, Grosser B I (1988) Decreased beta-adrenergic receptors in rat brain after chronic administration of the selective serotonin reuptake inhibitor fluoxetine. Psychopharmacology 94: 141-143
10. Caley C F, Friedman J H (1992) Does fluoxetine exacerbate Parkinson's disease? J Clin Psychiat 53: 278-282
11. Ciarcha G, Smokcum R W J, Stephenson J D, Weiramanthri T B (1985) Effects of some atypical antidepressants on beta-adrenoceptor binding and adenylate cyclase activity in the rat forebrain. Eur J Pharmac 108: 1-7
12. Contreras P C, Contreras M L, O'Donohue T L, Cecelia C L (1988) Biochemical and behavioural effects of sigma and PCP ligands. Synapse 2: 240-243
13. George M S, Trimble M R (1993) Dystonic reaction associated with fluvoxamine. J Clin Psychopharmac 13: 220-221
14. Goldstein S R, Matsumoto R R, Thompson T L, Patrick R L, Bowen W D, Walker J M (1989) Motor effects of two sigma ligands mediated by nigrostriatal dopamine neurons. Synapse 4: 254-258
15. 3H-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine. J Neurosci 6: 1757-1770
16. Hamilton M S, Opler L A (1992) Akathesia, suicidality and fluoxetine. J Clin Psychiat 53: 401-406
17. Hanner M, Moebius F F, Flandorfer A, Knaus H-G, Striessnig J, Kempner E, Glossmann H (1996) Purification, molecular cloning, and expression of the mammalian sigmal-binding site. Proc Nat Acad Sci USA 93: 8072-8077
18. Hemstreet M K, Matsumotso R R, Bowen W D, Walker J M (1993) σ Binding parameters in developing rats predict behavioural efficacy of a σ ligand. Brain Res 627: 291-298
19. Hornykiewicz O, Kish S J, Becker L E, Farley I, Shannak K (1986) Brain neurotransmitters in dystonia musculorum deformans. New Eng J Med 315: 347-353
20. Hyttel J (1994) Pharmacological characterisation of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmac 9: 19-26
21. Jankovic J, Svendsen C N (1987) Brain neurotransmitters in dystonia. New Eng J Med 316: 278-279
22. Johnson A M (1991) The comparative pharmacological properties of selective serotonin reuptake inhibitors in animals. In Feighner J P, Boyer W F (eds) Selective serotonin reuptake inhibitors. Perspectives in psychiatry, Vol. 1. John Wiley, Chichester, pp. 37-70
23. Katz J L, Spearman R D Clark R D (1985) Stereoselective behavioural effects of N-allylnormetazocine in pigeons and squirrel monkeys. J Pharmac Exp Therap 232: 452-461
24. 3H]SCH23390 binding sites in rat striatum and limbic system. Eur J Pharmac 139: 163-169
25. Kruskal W H, Wallis W A (1952) Use of ranks in one-criterion variance analysis. J Am Stat Ass 47: 583-621
26. Lane R, Fischler B (1995) The serotonin syndrome: coadministration, discontinuation and washout periods for the selective serotonin reuptake inhibitors (SSRIs). J Serotonin Res 3: 171-180
27. 3H] (+)-3-(3-hydroxy-phenyl)-N-(1-propyl) piperidine ((+)-3-PPP). Neurobiology 81: 4983-4987
28. 2 binding in rat brain. Eur J Pharmac 259: 65-69
29. Leonard B E, Faherty C J (1996) SSRIs and movement disorders: Is serotonin the culprit ? Human Psychopharmac 11: S75-S82
30. Lipinski J F, Mallya G, Zimerman R N (1989) Fluoxetine induced akathsia: clinical and theoretical implications. J Clin Psychiat 50: 339-342
31. Mann H B, Whitney D R (1947) On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat 18: 50-60
32. Mannalack D T, Beart P M, Gundlach A L (1986) Psychotomimetic σ-opiates and PCP.Trends Pharmac Sci 7: 448-451
33. Martin W R, Eades C E, Thompson J A, Huppler R E (1976) The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmac Exp Therap 197: 517-532
34. McLean S, Weber E (1988) Autoradiographic visualisation of haloperidol-sensitive sigma receptors in guinea-pig brain. Neuroscience 25: 259-269
35. Matsumoto R R, Walker J M (1988) Inhibition of rubral neurons by a specific ligand for σ receptors. Eur J Pharmac 158: 161-165
36. Matsumoto R R, Walker J M (1992) Iontophoretic effects of sigma ligands on rubral neurons in the rat. Brain Res Bull 29: 419-425
37. Matsumoto R R, Bowen W D, Walker J M (1989) Down regulation of sigma receptors by haloperidol. In Quirion R, Jhamandas K, Gianoulakis C (eds) Progress in clinical biological research, Vol. 328. Alan R. Liss, New York, pp. 125-128
38. Matsumoto R R, Hemstreet M K, Lai N L, Thurkauf A, De Costa B R, Rice K C, Hellewell S B, Bowen W D, Walker J M (1990) Drug specificity of pharmacological dystonia. Pharmac Biochem Behav 36: 151-155
39. Matsumoto R R, Bowen W D, Walker J M, Patrick S L, Zambon A C, Vo, V N, Truong D D, De Costa B R, Rice K C (1996) Dissociation of the motor effects of (+)-pentazocine from binding to σ1 sites. Eur J Pharmac 301: 31-40
40. Meltzer H Y, Young M, Metz J, Fang V S, Schyue P M, Arora R C (1979) Extrapyramidal side-effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Trans 45: 165-175
41. Mitchell P B (1994) Selective serotonin reuptake inhibitors: adverse effects, toxicity and interactions. Adv Drug React Toxic Rev 13(3): 121-144
42. Paxinos G, Watson C (1982) The rat brain in stereotaxic coordinates. Academic Press, New York
43. Quirion R, Bowen W D, Itzhak Y, Junien J L, Mussachio J M, Rothman R B, Su T P, Tam W, Taylor D P (1992) A proposal for the classification of sigma binding sites. Trends Pharmac Sci 13: 85-86
44. Rothschild A J, Locke C A (1991) Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. J Clin Psychiatry 52: 491-493
45. 3H]3-PPP binding to sigma sites in rat brain. Eur J Pharmac 165: 335-336
46. Steur E N H J (1993) Increase of Parkinsonian disability after fluoxetine medication. Neurology 43: 211-213
47. Stoukides J A, Stoukides C A (1991) Extrapyramidal symptoms upon discontinuation of fluoxetine. Am J Psychiat 148: 1263-1275
48. Su T P, London E D, Jaffe J H (1988) Steroid binding at σ receptors suggests a link between endocrine, nervous and immune systems. Science 240: 210-221
49. Sulser F, Mishra R (1982) Regulation of central noradrenergic receptor function and its relevance to the therapy of depression. In Langer S Z, Takahashi R, Briley M (eds) New vistas in depression. Pergamon Press, Oxford, pp. 37-47
50. Tam S W (1983) Naloxone-inaccessible sigma receptor in rat central nervous system. Proc Nat Acad Sci USA 80: 6703-6707
51. 3H] haloperidol binding in guinea pig brain membranes. Proc Nat Acad Sci USA 81: 5618-5623
52. Tam S W, Zhang A Z (1988) Sigma and PCP receptors in human frontal cortex membranes. Eur J Pharmac 154: 343-344
53. Tolosa E, Montserrat L, Bayes A (1988) Blink reflex studies in focal dystonias: Enhanced excitability of brainstem interneurons in cranial dystonia and spasmodic torticollis. Mov Disorders 3: 61-69
54. 2 and sigma binding sites in human brain in vitro. Eur Neuropsychpharmac 5(3): 280, P-2-21
55. Vetulani J, Antkiewicz-Michaluk L, Rokosz-Pelc A, Pilc A (1984) Alpha up-beta down adrenergic regulation: a possible mechanism of action of antidepressant treatments. Pol J Pharmac Pharm 36: 231-248
56. Walker J M, Bowen W D, Walker F O, Matsumoto R R, DeCosta B, Rice K C (1990) Sigma receptors: Biology and function. Pharmac Rev 42: 355-402
57. 3H]tolyl)guanidine: a selective ligand that labels sigma type receptors for psychotomimnetic opiates and antipsychotic drugs. Proc Natl Acad Sci USA 83: 8784-8788
58. Weissman A D, Su T P, Hedreen J C, London E D (1988) Sigma receptors in post-mortem human brains. J Pharmac Exp Ther 247: 29-33